Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2024 | 2025 | |
|---|---|---|
| Revenue | $526.0M | $381.2M |
| Cost of revenue | $0 | $64.8M |
| Gross profit | $0 | $316.4M |
| Gross margin | 0.0% | 83.0% |
| R&D | $0 | $0 |
| Operating income | $94.5M | $166.7M |
| EBITDA | $9.6M | $200.7M |
| Net income | $83.8M | $146.2M |
| Net margin | 15.9% | 38.4% |
| EPS (diluted) | 0.36 | 0.99 |
Annual figures · source: Financial Modeling Prep
No one on the platform currently holds FGNA.
No tracked institution reports a position in FGNA as of their last filing.
No one on the platform has traded FGNA yet.
| +12.74% |
| $134M |
| — |
| LSAQLifeSci Acquisition II Corp. | $9.01 | -1.96% | $1.1B | — |
| PACETPG Pace Tech Opportunities Corp. | $11.20 | +0.00% | $1.1B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.